Clinical trials: Complete Pathological Response
Breast Cancer
Histology VABB-Histology Post Surgery Pilot Project (BETTY Trial)
Pilot study on patients with invasive ductal breast cancer triple negative or receptor tyrosine-protein kinase erbB-2 (HER2) overexpressed, any axillary lymphnodes status (any cN), candidates to neoadjuvant chemotherapy.
- Trial name
- BETTY (NCT04365803)
- Testing
- vacuum-assisted breast biopsy
- Where
- Italy
- Volunteers
- 22 people
- Sponsor
- European Institute of Oncology
Non-small Cell Lung Cancer, Neoadjuvant Chemoimmunotherapy
Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer
The purpose of this study is to evaluate the performance of a CT/PET/ WSI-based deep learning signature for predicting complete pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer
- Conditions
- Non-small Cell Lung Cancer, Neoadjuvant Chemoimmunotherapy, Complete Pathological Response
- Trial name
- NCT05925751
- Testing
- CT/PET/WSI-based Deep Learning Signature
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Breast Cancer, HER2-positive Breast Cancer
NearWave Optical Molecular Monitoring
The purpose of this study is to assess the feasibility of the NearWave optical molecular monitoring system for monitoring therapy progression and predicting pathologic complete response (pCR) of breast cancer patients undergoing…
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer
- Trial name
- NCT06744465
- Testing
- NearWave monitoring
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Indiana University
Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
The purpose of this study was to allow continued use of nilotinib in patients who were on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs (CD\&MA) study and were benefiting from the…
- Conditions
- Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma
- Trial name
- NCT01735955
- Testing
- Nilotinib
- Where
- 33 sites in United States, Austria and 14 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Triple Negative Breast Neoplasms
A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug taxane, will improve the results of the treatment for early- stage Triple Negative Breast…
- Conditions
- Breast Cancer, Triple Negative Breast Neoplasms, Triple-Negative Breast Neoplasm, Triple-Negative Breast Cancer
- Trial name
- NCT02685306
- Testing
- Bavituximab, Taxane
- Sponsor
- Peregrine Pharmaceuticals
Chronic Hepatitis C
The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C
The efficacy of combination antiviral therapy for chronic hepatitis C is influenced by many factors. Important patient-specific factors include, age, gender, race, body weight.
- Trial name
- NCT01464008
- Testing
- Pegylated interferon alfa-2a and ribavirin
- Where
- China
- Volunteers
- 297 people
- Sponsor
- Beijing Ditan Hospital
Prostate Cancer
Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)
This study evaluates the use of chemotherapy with cabazitaxel in addition to abiraterone acetate, prednisone, and leuprolide in neoadjuvant setting prior to radical prostatectomy in patients with high-risk prostate carcinoma.
- Trial name
- ACDC-RP (NCT02543255)
- Testing
- Abiraterone acetate with prednisone, Leuprolide, Cabazitaxel with peg-filgrastim
- Where
- 5 sites in Canada
- Volunteers
- 76 people
- Sponsor
- University Health Network, Toronto
Esophageal Cancer
Risk Factors of Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to Neoadjuvant Chemoradiotherapy
It has been reported that patients with esophageal squamous cell carcinoma who achieved pathological complete response (PCR) to neoadjuvant chemoradiotherapy have better survival than those with non-PCR.
- Trial name
- NCT06061263
- Testing
- follow up
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Sun Yat-sen University
Triple-Negative Invasive Breast Carcinoma, Residual Tumor
Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients
Triple-negative breast cancer (TNBC) refers to any breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR) or Her2/neu. Its incidence is approximately 180,000 cases per year.
- Trial name
- NCT02670109
- Testing
- Carmustine, Cyclophosphamide, Carboplatin
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Acute Myeloid Leukemia
Sulindac for Patients With AML
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug is effective in treating a specific cancer.
- Trial name
- NCT01843179
- Testing
- Cytarabine, Sulindac
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Breast Cancer
Evaluation of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT for Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in HER2 Positive Early Breast Cancer
The GATHER trial aim to evaluate the diagnostic performance of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT in predicting pCR following neoadjuvant chemotherapy.
- Trial name
- GATHER (NCT07593976)
- Testing
- [68Ga]Ga-NOTA-anti-HER2-sdAb Positron Emission Tomography
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Centre Henri Becquerel
Breast Neoplasm
Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy.
The purpose of this study is to evaluate the ability of preoperative biopsy to predict correctly pathologic complete response in breast cancer patients with complete clinical response after neoadjuvant chemotherapy.
- Trial name
- NCT03273426
- Testing
- Minimally-invasive biopsy, wide excision
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Seoul National University Hospital
Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia
Some patients with antibody-mediated autoimmune hematological diseases (warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (cAIHA) and immune thrombocytopenia (ITP)) shows no or only minor and transient response to…
- Trial name
- Ixa-Cyto (NCT03965624)
- Testing
- Ninlaro
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Leukemia, Myeloid
A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML
It is often impossible to find therapeutic target in intermediate-risk AML, so it is very important to select appropriate chemotherapy protocol to eliminate minimal residual disease (MRD) in these AML patients.
- Trial name
- NCT03417427
- Testing
- Decitabine and Ara-C, Ara-C
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xuejie Jiang
HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
This randomized phase III trial studies docetaxel, carboplatin, trastuzumab, and pertuzumab with estrogen deprivation to see how they work compared to docetaxel, carboplatin, trastuzumab, and pertuzumab without estrogen…
- Conditions
- HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7
- Trial name
- NCT02003209
- Testing
- Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure
- Where
- 732 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- National Cancer Institute (NCI)
Metabolism and Nutrition Disorder, Metabolic Disturbance
Markers of Carnitine Acetyltransferase (CrAT) Protein Activity and Carnitine Availability
This study aims to measure skeletal muscle metabolism in vivo during exercise using the non-invasive Magnetic Resonance Spectroscopy (MRS) technique.
- Trial name
- NCT03697928
- Testing
- Exercise metabolism
- Where
- Netherlands
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Maastricht University
Gastric Cancer (GC), Locally Advanced Gastric Cancer
Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
Gastric cancer is a major global health challenge. Currently, a combination of chemotherapy and immunotherapy (PD-1 inhibitors) is frequently used before surgery to shrink tumors, a strategy known as neoadjuvant therapy.
- Trial name
- NCT07401199
- Testing
- Standard of Care PD-1 Inhibitors, Multimodal AI Assessment
- Where
- 9 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Qun Zhao
Invasive Breast Cancer
Adding Preoperative Radiotherapy Based on Early Treatment Response in Breast Cancer
RAPID-NeoBC is a prospective, multicentre, response-adapted study with a randomized component for adults with operable, nonmetastatic invasive breast cancer receiving guideline-recommended neoadjuvant systemic therapy.
- Trial name
- RAPID-NeoBC (NCT07892508)
- Testing
- Response-adapted preoperative radiotherapy, Guideline-recommended neoadjuvant systemic therapy, Serial contrast-enhanced breast MRI and breast-specific gamma imaging
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer
INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer
This is a phase II, randomized, multi-center, parallel design, window of opportunity trial evaluating intratumoral INT230-6 in up to 90 patients with early stage breast cancer.
- Trial name
- NCT04781725
- Testing
- INT230-6, Saline injection
- Where
- Canada
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Ottawa Hospital Research Institute
Breast Cancer
Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer
This study is being done to see if it is possible to use blood samples to predict response to treatment in breast cancer patients receiving preoperative (or neoadjuvant) therapy.
- Trial name
- NCT02743910
- Testing
- ptDNA, Tissue sample
- Where
- United States
- Volunteers
- 228 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins